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Abstract
An international survey was conducted in 927 men with advanced prostate cancer (aPC) and 400 caregivers to
assess symptom communication. Patients with aPC often ignore pain and pain-related symptoms, do not
discuss pain with their physician, and have difﬁculty discussing symptoms. Effective communication among
patients, caregivers, and health care providers may improve symptom and disease management and patient
quality of life.
Background: Bone metastases in men with prostate cancer are often initially asymptomatic, resulting in delayed
identiﬁcation, diagnosis, and appropriate treatment.To assess how patients with advanced prostate cancer (aPC)
communicate symptoms to health care providers, an international patient survey was conducted. Methods: An online
and phone survey was conducted by Harris Poll in 11 countries (Brazil, France, Germany, Japan, Italy, Netherlands,
Singapore, Spain, Taiwan, United Kingdom, United States) from February 12 to October 27, 2015, in men with aPC (ie,
those who reported as having PC beyond the prostate [metastatic]) and their caregivers.Cell weighting was used to
ensure equal weight of data across countries. Percentages are based on weighted n values. Results: A total of 927
men with aPC (weighted n ¼ 664) and 400 caregivers completed the survey. Most commonly reported symptoms were
fatigue (73%), urinary symptoms (63%), sexual function symptoms (62%), and bone pain (52%). Of 568 patients with
bone metastases (weighted n ¼ 421), most (73%) noticed pain before receiving a diagnosis of metastatic PC. Most
patients with aPC (56%) were uncertain if their pain was cancer related, 55% felt they had to live with daily pain, 45%
sometimes ignored pain, and 39% had difﬁculty talking about pain. Patients who had a caregiver were more likely than
those without to discuss pain at every visit (45% vs. 32%, P < .05). Conclusions: Disease symptoms in aPC are often
underrecognized. Tools encouraging effective communication among patients, caregivers, and health care providers
on early symptom reporting may lead to enhanced symptom and disease management.
Clinical Genitourinary Cancer, Vol. -, No. -, --- ª 2017 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer (PC) is the second most common malignancy in
men worldwide, with an estimated 1.1 million men across the world
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PC is an androgen-dependent disease that initially responds to
androgen-deprivation therapy (ie, chemical or surgical castration).
However, most men will become resistant to androgen-deprivation8Queen’s University School of Medicine, Belfast, UK
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Advanced Prostate Cancer Global Surveytherapy over time, developing nonmetastatic castration-resistant PC
(CRPC), in which a rise in prostate-speciﬁc antigen is often the ﬁrst
detectable sign.2-4 For some men, nonmetastatic CRPC will
progress to metastatic CRPC, which is still uniformly incurable,
although several new treatment options have been shown to
signiﬁcantly improve survival, including traditional taxane chemo-
therapy (docetaxel), new androgen-receptor pathway antagonists
(enzalutamide, abiraterone), novel taxanes (cabazitaxel), immuno-
therapy (sipuleucel-T), and targeted alpha therapy (radium-223).5,6
A large majority of men with metastatic CRPC (90%) will
develop bone metastases, which are often initially asymptomatic.6,7
Although a small proportion of patients are de novo diagnosed with
metastatic disease, most bone metastases develop in patients who
have failed local treatment and progress under androgen-deprivation
therapy. Bone metastases are strongly associated with increased
mortality in men with metastatic CRPC, and the risk of death is
even higher in men with skeletal-related events.8,9 In addition to
increased mortality, bone metastases are a major cause of disability,
bone pain, impaired quality of life (QoL), and excessive treatment
costs.6,10 Pain is the most common symptom, occurring in 75% of
symptomatic patients with metastatic PC,7 whereas spinal cord
compression occurs in up to 12% of patients and may be the ﬁrst
sign of bone metastases.11
To better understand the symptoms associated with advanced PC
(aPC) and the impact of symptoms on the lives of patients and their
caregivers, an international survey was commissioned by the Inter-
national Prostate Cancer Coalition. The goals of the survey were to
describe the disease burden, highlight barriers that prevent men
from discussing symptoms, explore the patient-caregiver dynamic,
and raise awareness of the importance of discussing symptoms with
health care providers.
Patients and Methods
This survey (see Supplemental Figure 1 for full survey ques-
tionnaire) was conducted online and by phone by the Harris Poll
in Brazil, Europe (France, Germany, Italy, the Netherlands, Spain,
and the United Kingdom), Asia-Paciﬁc region (APAC; Japan,
Singapore, and Taiwan), and the United States from February 12,
2015, to October 27, 2015. The survey was provided to
respondents in the following local languages: American English,
British English, German, French (France and Belgium), Italian,
Spanish, Dutch (Netherlands and Belgium), Japanese, Traditional
Chinese (Taiwan), and Portuguese (Brazil). After the surveys were
translated from the US English version to the local language by
local translators, the surveys were then reviewed by in-country
representatives familiar with the survey topic to ensure that the
meaning of the questions would be understood in the same way
across the different countries.
Survey respondents were selected from among individuals who
had agreed to participate in surveys through the Harris Poll and
their partners or were recruited to participate by patient advocacy
organizations. Sampling methods included a convenience sample
from patient advocacy organizations. Respondents were included
in the survey if they lived in 1 of the 11 participating countries,
were aged 18 years, and had a diagnosis of aPC (respondents
reported having PC in locations other than the prostate). A care-
giver was deﬁned as someone who had provided unpaid care to anical Genitourinary Cancer Month 2017friend or family member diagnosed with aPC. Patient care may
have included providing support or assistance to a friend or family
member; however, this deﬁnition did not include care provided by
a health care professional or someone with formal volunteering
experience. Eligible caregivers were aged 18 years, were caring
for someone with aPC, and lived in the same country in which the
patient lived. Informed consent was obtained at the start of the
online survey.
Demographic information was obtained from all respondents.
Questions included in the survey assessed general health, concerns
about personal health, symptoms, challenges faced living with aPC,
and comfort level when speaking with health care providers.
The sample was based on the individuals who agreed to partici-
pate in panels or advocacy groups; therefore, it was not possible to
estimate a theoretical sampling error. Because sample sizes varied
between countries, the ﬁndings were adjusted to ensure that data
from all countries received an equal weight in global and regional
data analyses. Country-level data were unweighted. Data were
analyzed using descriptive statistics, cross-tabulations, and correla-
tions. Between-group differences were analyzed using a standard t
test at the 95% conﬁdence level (P < .05). Because of the small base
size, comparisons versus APAC and Brazil are directional in nature
and should be interpreted with caution.
Results
The study sample consisted of 927 men with aPC (weighted
n ¼ 664) and 400 caregivers who responded to the survey and met
eligibility requirements; the overall weighted n value of 664 or the
weighted n values by country, as indicated later in this article, were
used to calculate the reported percentages. Overall, the mean patient
age was 65.7 years, and 86% (n ¼ 570) of patients had a caregiver.
Patients from the United States and Europe were similar in age
(mean, 67.9 and 67.8 years, respectively), as were patients from the
APAC and Brazil (61.7 and 62.6 years) (Table 1).
In the total population, 84% of the men had been diagnosed
with PC for longer than 12 months (Table 1). Among patients with
aPC, the bone compartment was the most observed site for me-
tastases, followed by lymph node involvement. Most patients in all
regions had conﬁrmed bone metastases (Table 1).
Most patients had caregivers, with the proportion somewhat
greater in the APAC and Brazil compared with Europe and the
United States (Table 1). Of the caregiver respondents in the
United States, 63% (60/95) were patients’ spouses or partners
compared with 49% (179/362) in Europe and 43% (17/40) in
Brazil. In contrast, caregivers in the APAC were primarily patients’
offspring (126/181, 70%). Most caregivers were women (n ¼ 520,
78%) with a mean age of 52 years. Differences in employment
status were apparent between patients and caregivers. More pa-
tients were retired compared with caregivers (n ¼ 325, 49% vs.
n ¼ 160, 24%), with more than twice as many caregivers working
full- or part-time (n ¼ 199, 30%) compared with patients (n ¼
86, 13%). Patients were accompanied by caregivers to 70% of
their physician visits on average, and 50% (n ¼ 330) of patients
relied on a spouse or caregiver to ask the most important questions
about their PC issues.
Nearly all patients reported facing challenges related to their PC,
the most common of which was a decreasing ability to maintain
Table 1 Patient Demographic and Disease Characteristics
Parameter USA (n [ 410) EU (n [ 349) APAC (n [ 108) Brazil (n [ 60) Total (n [ 927)
Mean age (SD), y 67.9 (10.1) 67.8 (8.7) 61.7 (7.5) 62.6 (12.8) 65.7 (9.4)
Patient has a caregiver, % 78 84 90 90 86
Time since prostate cancer
diagnosis, % of patients
0e12 mo 6 11 26 23 16
>12 mo 94 89 74 77 84
Location of observed
metastases, % of patientsa
Bone 53 72 53 53 63
Lymph nodes 40 29 38 2 30
Liver 3 6 3 40 8
Lung 4 7 2 17 6
Other 16 11 19 13 14
Not sure 8 5 1 2 4
Abbreviations: APAC ¼ Asia-Paciﬁc region; EU ¼ European Union; USA ¼ United States of America.
aSum of percentages is >100% because some patients had metastases in >1 location.
Lawrence Drudge-Coates et altheir lifestyle (n ¼ 359, 54%). Caregivers most commonly reported
pain management (n ¼ 394, 59%) and the emotional impact on the
patients’ family (n ¼ 390, 59%) as the most prominent challenges
faced by the patient (Figure 1).
The most commonly reported symptoms were fatigue (n ¼ 483;
73%), urinary symptoms (n ¼ 420; 63%), sexual function symp-
toms (n ¼ 408; 62%), and bone pain (n ¼ 344; 52%). Regional
differences in symptom reporting were identiﬁed (Figure 2). The
symptoms most reported by region were sexual function by patients
from the United States, fatigue by patients from Europe, urinary
symptoms by patients from the APAC, and weight loss by patients
from Brazil. Spain had the highest proportion of patients with
symptoms of depression/anxiety (n ¼ 83, 86%), confusion (n ¼ 68,
71%), and difﬁculty sleeping (n ¼ 76, 79%). Bone pain was
reported by signiﬁcantly fewer patients in the United States
(n ¼ 119, 29%) than in Europe (n ¼ 200, 55%; P < .05) or the
APAC (n ¼ 92, 51%; P < .05) (Figure 2). Of 568 patients with
bone metastases (weighted n ¼ 421), the most frequently reported
symptoms were fatigue (n ¼ 367, 87%); pain in speciﬁc areas, such
as the back, pelvis, and hips (n ¼ 349, 83%); and generalized body
pain (n ¼ 303, 72%). Spain had the highest proportion of patients
with bone fractures or broken bones (unweighted n ¼ 62, 76%).
Most patients with bone metastases (n ¼ 309, 73%) noticed pain
before receiving a diagnosis of metastatic PC (n ¼ 167, 40% had
pain for 7 months; n ¼ 142, 34% for <7 months). The per-
centage of patients who had pain for 7 months before receiving a
diagnosis of metastatic PC varied widely by country (range: 3/29,
10% in Japan to 55/82, 67% in Spain).
In 71% of patients (470/664), managing pain was identiﬁed as
essential for effective cancer management. Men in the United States
(365/410, 89%) were more likely to strongly agree with feeling
comfortable discussing their symptoms and pain with their physi-
cian compared with men in Europe (221/362, 61%) and the APAC
(98/181, 54%). However, 39% (261/664) of patients agreed that it
was difﬁcult to talk about the amount of pain they were experi-
encing. Among patients who told their physicians about their pain(n ¼ 320), more patients from the United States waited 1 month
to tell their physician compared with patients in Europe (Figure 3).
More men in Europe (208/362, 57%), the APAC (117/181, 65%),
and Brazil (37/60, 62%) than men in the United States (146/410,
36%) agreed that if that they acknowledged more pain, they would
fear that their cancer is progressing. Several misconceptions about
cancer-related pain were identiﬁed. Many patients with aPC were
uncertain if their pain was cancer related (Figure 4). Regional dif-
ferences also were identiﬁed. For example, patients in the United
States were less likely than patients in Europe or the APAC to
understand the relationship between their pain and aPC. Of note,
55% (n ¼ 368) of patients felt they had to live with daily pain, and
45% (n ¼ 301) sometimes ignored pain.
When asked to rate the severity of pain experienced over the past
week on a scale from 0 (no pain) to 10 (worst imaginable pain),
caregivers rated pain severity as higher for the men they cared for
than did the patients, on average (mean pain scores, 5.4 vs. 4.2,
respectively). Caregivers also estimated that 66% (n ¼ 435) of the
men they cared for had intermittent or constant bone pain
compared with 53% (n ¼ 351) of patients who rated their pain as
intermittent or constant. Signiﬁcantly more caregivers than patients
agreed with the statement that pain limited the patients’ activities
(n ¼ 479, 72% vs. n ¼ 359, 54%, respectively; P < .0001).
Patients who had a caregiver were more likely than those without a
caregiver to state that pain was discussed at every health care visit
(45% vs. 32%, P < .05).
Regional differences in the effect of pain on daily living and
emotional health were observed. Compared with other countries
or regions, patients in the United States were less likely to see pain
as limiting their activities or as a barrier to living their lives
(Figure 5). Most patients stated they would be motivated to report
pain to their physician if it helped increase their QoL (n ¼ 433,
65%) or longevity (n ¼ 381, 57%), kept cancer from worsening
(n ¼ 359, 54%), or decreased cancer-related pain (n ¼ 354, 53%).
The use of prescription and over-the-counter (OTC) medications
for pain management was common in this population. Overall,Clinical Genitourinary Cancer Month 2017 - 3
Figure 1 Challenges Faced by Patients With Advanced Prostate Cancer and Their Caregivers. aP < .05
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4 - Cli52% (n ¼ 348) of patients used prescription analgesics, and 31%
(n ¼ 209) used OTC pain relief medications. Patients in the
United States were less likely to report using prescription analge-
sics (102/410, 25%) than patients in Europe (179/362, 49%;
P < .05), the APAC (106/181, 59%; P < .05), or Brazil (48/60,
80%; P < .05), and were more likely to report using OTC
analgesics (233/410, 57%; P < .05) than patients in Europe (134/
362, 37%), the APAC (31/181, 17%), or Brazil (10/60, 17%;
P < .05). Of the 375 patients who used OTC analgesics, 53%
(n ¼ 110/209) used them at least several times a week and 32%
(n ¼ 66/209) did so at least once daily.
Overall, 52% (n ¼ 348) of patients were treated by oncologists
and 28% (n ¼ 188) by urologists. Signiﬁcantly more patients in the
United States (290/410, 71%) and Brazil (53/60, 88%) were
treated by oncologists than in Europe (201/362, 56%; P < .05) or
the APAC (51/181, 28%; P < .05). More patients in the United
States (393/410, 96%) and the APAC (173/181, 96%) compared
with Europe (304/362, 84%) and Brazil (34/60, 57%) stated their
physician involved them in treatment decisions (P < .05). Most
patients (n ¼ 586, 88%) reported that physicians were most likelynical Genitourinary Cancer Month 2017to ask them how they were feeling (eg, including inquiries about
pain and fatigue), whereas patients reported that nurses (n ¼ 228,
34%), physician assistants (n ¼ 145, 22%), or other staff members
(n ¼ 44, 7%) did so less often. European and Brazilian patients
were signiﬁcantly more likely than their US counterparts to report
that physicians ask how they were feeling (327/362, 90% and 57/
60, 95% vs. 333/410, 81%; P < .05). However, patients in the
United States (226/410, 55% and 137/410, 33%, respectively) and
the APAC (76/181, 42% and 78/181, 43%) were signiﬁcantly more
likely to report nurses and physician assistants inquire about how
patients were feeling than those in Europe (86/362, 24% and 37/
362, 10%; P< .05). In Brazil, 55% (33/60) of patients reported the
same for nurses (which was signiﬁcantly higher vs. Europe), and
15% (9/60) for physician assistants.
Discussion
This study of men with aPC and caregivers for patients with aPC
is the largest symptom survey in this population to date and showed
that the most frequently reported symptoms were fatigue, urinary
symptoms, sexual function, and bone pain. Many patients ignore
Figure 2 Patient Reports of Prostate Cancer Symptoms Since Diagnosis
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51a
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Lawrence Drudge-Coates et alpain and do not bring it to the attention of their physician, possibly
delaying the diagnosis of aPC or a proper course of treatment.
Patients oftentimes have difﬁculty talking about their pain, believing
that such conversations may make them appear to be weak. More
than half of patients surveyed believe that daily pain or discomfort is
something they need to endure and admit that they do not always
know if their pain is related to cancer or to something else. Half of
patients admitted that they rely on their caregivers to ask the most
important questions about their PC; thus, the absence of a caregiver
during an ofﬁce visit represents a potential missed opportunity for
relevant discussions with the physician. More than half of the men
surveyed agreed that they would be more likely to discuss their
symptoms if doing so increased their QoL, helped prolong their life,
halted the development of metastatic disease, or increased their
physical activity level. However, regional differences suggested that
compared with men from the United States, those from Europe and
APAC were not as comfortable discussing their physical well-being;
additionally, men from Europe and APAC were more likely than
men from the United States to fear that acknowledging pain means
that their cancer is progressing.
This survey demonstrated that symptoms of aPC are recognized
by patients and caregivers with varying degrees and inﬂuenced byglobal regional differences. Overall, patients with aPC noted
symptoms inclusive of fatigue, lack of energy, pain (especially
persistent pain requiring daily use of analgesics), weight loss, anxi-
ety, leg weakness, loss of bladder or bowel control, and impaired
interpersonal relationships.5,12
Unfortunately, many of these symptoms are relatively nonspeciﬁc
(eg, fatigue, pain) and may be attributed to the everyday aches and
pains associated with aging.13 However, because the presence of
symptoms or changes in their frequency or severity may indicate
disease progression, failure to address them in a timely manner may
affect optimal diagnosis and treatment discussions.14 Effective
communication between patients or caregivers and health care
providers about early symptom reporting should lead to effective
disease management earlier in the course of the disease.
The assessment of symptoms experienced by patients with cancer
and their relation to outcomes and QoL have been the subject of
several recent studies.15-18 A steering committee from the National
Cancer Institute identiﬁed a core set of 12 symptoms that could be
monitored in cancer treatment trials to improve cross-study com-
parisons of symptomatic effects. The core set of symptoms included
anorexia, anxiety, cognitive problems, constipation, depression,
diarrhea, dyspnea, fatigue, insomnia, nausea, pain, and sensoryClinical Genitourinary Cancer Month 2017 - 5
Figure 3 Duration of Time Patients Waited to Report Pain to Their Physician
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6 - Clineuropathy.15 Studies speciﬁc to PC symptoms have also been
conducted.16-18 Active surveillance in men with low-risk PC iden-
tiﬁed the lack of a partner, mental health issues, lack of input from
physicians other than the primary physician, and fewer core biopsyFigure 4 Patient Uncertainty About the Relationship of Pain and Ca
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The validity of the MD Anderson Symptom Inventory (MDASI),
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demonstrated that the MDASI was highly sensitive in detecting
disease progression and treatment response, as well as QoL based on
changes in symptoms in this population.17 Physician-patient
communication and shared decision making could beneﬁt from
the availability of instruments such as the MDASI. However, the
quality of communication between patients and health care pro-
viders remains an area for improvement. Findings from a recent
survey administered by the National Cancer Institute demonstrated
few conversations between patients and physicians about PC
screening and treatment options and, by extension, limited oppor-
tunity for shared decision making.18
Regional differences in patients’ experiences with metastatic
cancer have been reported previously.19 Results from a large global
survey found that patients with advanced metastatic breast cancer in
the United States were more likely to report feelings of isolation,
that others misunderstand their cancer experience, and diminishing
support from family and friends compared with patients from other
countries.19
Participation in surveys may improve patient outcomes, as
demonstrated by a trial of symptom monitoring in 766 patients
undergoing chemotherapy.20 Patients with advanced solid tumors
(metastatic breast, genitourinary, gynecologic, or lung) who were
randomized to self-report symptoms using a Web-based survey
achieved signiﬁcant beneﬁts compared with patients randomized to
usual care in terms of fewer reductions in health-related QoL scores
(38% vs. 53%; P < .001) and fewer emergency room visits (34%vs. 41%; P ¼ .02).20 Moreover, after a median follow-up of 7 years,
median overall survival for patients self-reporting symptoms was 5
months longer than those receiving usual care (31.2 vs. 26.0
months, P ¼ .03).21
Online educational tools are available to encourage communi-
cation between patients or caregivers and health care professionals.
The “Men Who Speak Up” Web site (https://www.
menwhospeakup.com/index.php) is a resource for patients
designed to increase awareness about symptoms and encourage men
to seek medical help if they notice symptoms associated with PC.
These materials encourage men to seek medical help if they are
experiencing difﬁculties performing regular activities, taking more
pain relievers than normal, or having aches or pains that cannot be
attributed to a speciﬁc cause. Additional materials include a patient
symptom tracker for patients to provide detailed information on
mobility, usual activities, mood, fatigue, sleep, QoL, and pain that
can be used by their physician to evaluate symptoms. The Managing
Advanced Cancer Pain Together (MACPT) Web site (http://www.
macpt.eu/) is another resource that offers guidance on the
management of cancer pain.22 The MACPT comprises a multi-
disciplinary group of cancer pain management specialists who have
drawn on their expertise and current best practice guidelines to offer
guidance on the management of pain in the advanced cancer setting.
Materials on the MACPT Web site are aimed toward training
health care providers, but they can be used by patients and care-
givers as a tool to help initiate discussions about cancer pain.22 The
CancerCare Web site (http://www.cancercare.org/tagged/doctor-Clinical Genitourinary Cancer Month 2017 - 7
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8 - Clipatient_communication) provides information and resources about
cancer for patients and their families.23 Information consists of
counseling services from oncology social workers, educational ma-
terials (eg, podcasts, workshops, publications), ﬁnancial assistance
information, and experts answering frequently asked questions.23
We recognize that the cross-sectional nature of our survey pre-
vented assessment of changes in attitudes and relationships over
time. Furthermore, the participants represented a convenience
sample of patients and caregivers who agreed to particpate in panels
or advocacy groups, thus possibly introducing selection bias into the
results. These factors should be considered when interpreting our
results. However, to our knowledge, the study reported here is the
largest survey of patients with aPC to date, especially with a global
population. Our results are strengthened by including patients and
caregivers from around the world and asking questions about
relationships with health care providers that represent a multidis-
ciplinary team approach to patient care. We expect that future
studies would include longitudinal assessments of patients with aPC
to conﬁrm our ﬁndings.
Conclusions
Disease symptoms in aPC are often underrecognized and may
have marked differences between patients and caregivers, as well as
signiﬁcant global variations. There is an unmet need for tools that
encourage effective communication between patients or caregivers
and health care providers on early symptom reporting, which may
lead to earlier symptom and disease management and resultant
improved QoL and patient outcomes. Our data support the
involvement of patients, caregivers, and allied health care pro-
fessionals in shared clinical decision making.
Clinical Practice Points
 Most men with metastatic PC will develop bone metastases.
Because bone metastases are often initially asymptomatic, they
may evade timely identiﬁcation by health care providers,
resulting in delayed diagnosis and appropriate treatment.
 An international survey conducted in 927 men with aPC and
400 caregivers identiﬁed fatigue, urinary symptoms, sexual
function symptoms, and bone pain as the most common
symptoms reported by patients with aPC. In addition, many
patients ignore pain and pain-related symptoms, do not bring it
to the attention of their physician, and have difﬁculty talking
about their pain, possibly delaying a diagnosis of aPC or a proper
course of treatment.
 Effective communication among patients, caregivers, and health
care providers may promote earlier symptom reporting, leading
to enhanced symptom and disease management, and improved
patient QoL and clinical outcomes.Acknowledgments
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